6660 Stock Overview
AIM Vaccine Co., Ltd. engages in the research and development, manufacturing, and commercialization of vaccine products for human use in the People’s Republic of China.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
AIM Vaccine Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$8.13 |
52 Week High | HK$55.40 |
52 Week Low | HK$6.06 |
Beta | 0 |
1 Month Change | 20.09% |
3 Month Change | 3.57% |
1 Year Change | -81.48% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -51.20% |
Recent News & Updates
Shareholder Returns
6660 | HK Biotechs | HK Market | |
---|---|---|---|
7D | 1.4% | -2.3% | -1.5% |
1Y | -81.5% | -41.4% | -13.9% |
Return vs Industry: 6660 underperformed the Hong Kong Biotechs industry which returned -41.4% over the past year.
Return vs Market: 6660 underperformed the Hong Kong Market which returned -13.9% over the past year.
Price Volatility
6660 volatility | |
---|---|
6660 Average Weekly Movement | 9.0% |
Biotechs Industry Average Movement | 9.9% |
Market Average Movement | 7.4% |
10% most volatile stocks in HK Market | 14.7% |
10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 6660 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6660's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2011 | 1,572 | Yan Zhou | https://www.aimbio.com |
AIM Vaccine Co., Ltd. engages in the research and development, manufacturing, and commercialization of vaccine products for human use in the People’s Republic of China. The company’s product pipeline includes Bivalent Delta-Omicron BA.5 mRNA and Monovalent Omicron BA.5 mRNA, which is in phase III clinical trails for the treatment of COVID-19; EV71-CA16 Bivalent for HFMD; and Valent Pneumococcal Conjugate and Polysaccharide vaccine for pneumococcal disease. It also offers Hexavalent group B Streptococcus Polysaccharide Conjugate Vaccine for Group B strep disease; Diphtheria, Tetanus and Pertussis and Haemophilus In¬uenzae type B, and Diphtheria, Tetanus and Acellular Pertussis, and Absorbed Tetanus for DTP; Haemophilus In¬uenzae Type B for Hib; and freeze-dried human rabies and mRNA human rabies vaccine.
AIM Vaccine Co., Ltd. Fundamentals Summary
6660 fundamental statistics | |
---|---|
Market cap | HK$9.85b |
Earnings (TTM) | -HK$1.41b |
Revenue (TTM) | HK$1.29b |
7.7x
P/S Ratio-7.0x
P/E RatioIs 6660 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6660 income statement (TTM) | |
---|---|
Revenue | CN¥1.19b |
Cost of Revenue | CN¥286.45m |
Gross Profit | CN¥901.02m |
Other Expenses | CN¥2.20b |
Earnings | -CN¥1.30b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.07 |
Gross Margin | 75.88% |
Net Profit Margin | -109.56% |
Debt/Equity Ratio | 45.3% |
How did 6660 perform over the long term?
See historical performance and comparison